Thanks bobby, this was just a quick compilation of things that caught my attention. There is a whole lot more in the interview. Everyone who is invested in BIEL should give it a couple of listens.
A few key issues that are important IMO:
* Dr. Scholl's is still progressing and will get done
* No question from FDA that would have stopped the 510k Clock
* Mundipharma added 5 more countries and BIEL is talking to them about adding more
* ActiPatch is in a good position to be successful in the Opioid Innovation Challenge which would be an extreme catalyst to BIEL's growth